The results show that the low expression of LMP2, PSME1, and PSME2 within the tumor is significantly correlated with a good pathological response (MPR) of patients to NACI, suggesting that they may influence treatment sensitivity by regulating antigen presentation and the immune microenvironment. Here, PSMB9 is linked to neoplasm.